Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan for Treatment of Portopulmonary Hypertension (PoPH): A Pilot Study
2011-001139-22Phase 2Terminated
- Sponsor
- Medical University of Graz, Department of Gastroenterology and Hepatology
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ambrisentan in portopulmonary hypertension (POPH), sponsored by Medical University of Graz, Department of Gastroenterology and Hepatology. Primary endpoint: Resting pulmonary vascular resistance. Started May 2011; status: terminated.
02
Drugs
ambrisentan
03
Conditions
portopulmonary hypertension (POPH)
Beyond the preview
Go deeper on 2011-001139-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001139-22.